OGN
Organon & Co.
+0.01 (+0.04%)13.68USD322K成交股數3.6B市值17.5本益比(近四季)0.6股價營收比-2.3%營收年增(近四季)2026-11-09下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.6B+3% | 1.5B-8% | 1.6B+1% | 1.6B-1% | 1.5B-7% | 1.6B+5% | 1.6B-2% | 1.6B+4% | 1.6B | 1.5B | 1.6B | 1.5B |
| 營業成本 | 711M | 677M | 745M | 720M | 672M | 696M | 659M | 668M | 665M | 612M | 640M | 580M |
| 毛利 | 847M+1% | 783M-13% | 857M-7% | 874M-7% | 841M-12% | 896M-1% | 923M-5% | 939M-2% | 957M | 907M | 968M | 958M |
| 毛利率 | 54.4% | 53.6% | 53.5% | 54.8% | 55.6% | 56.3% | 58.3% | 58.4% | 59.0% | 59.7% | 60.2% | 62.3% |
| 研發費用 | 90.0M | 93.0M | 84.0M | 95.0M | 96.0M | 130M | 111M | 116M | 112M | 137M | 128M | 129M |
| 銷售管理費用 | 434M | 424M | 415M | 453M | 420M | 470M | 422M | 437M | 431M | 538M | 451M | 435M |
| 營業利益 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業利益率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | 108M+24% | 146M+34% | 160M-55% | 145M-26% | 87.0M-57% | 109M+88% | 359M+48% | 195M+10% | 201M | 58.0M | 242M | 177M |
| 淨利率 | 6.9% | 10.0% | 10.0% | 9.1% | 5.8% | 6.8% | 22.7% | 12.1% | 12.4% | 3.8% | 15.0% | 11.5% |
| 稀釋 EPS | 0.40+21% | 0.55+31% | 0.61-56% | 0.56-25% | 0.33-58% | 0.42+83% | 1.38+45% | 0.75+9% | 0.78 | 0.23 | 0.95 | 0.69 |
| 稀釋股數 | 270M | 263M | 261M | 260M | 261M | 259M | 260M | 259M | 258M | 256M | 256M | 256M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.1B | 1.1B | 672M | 599M | 547M | 675M | 763M | 704M | 575M | 414M | 326M | 459M |
| 應收帳款 | 1.5B | 1.4B | 1.5B | 1.5B | 1.5B | 1.4B | 1.7B | 1.6B | 1.5B | 1.6B | 1.7B | 1.4B |
| 存貨 | 1.4B | 1.4B | 1.5B | 1.5B | 1.4B | 1.3B | 1.4B | 1.3B | 1.3B | 1.2B | 1.2B | 1.1B |
| 總資產 | 13.2B | 13.0B | 13.6B | 13.5B | 13.2B | 13.1B | 12.8B | 12.2B | 11.9B | 11.0B | 11.0B | 10.8B |
| 有息負債 | 8.5B | 8.6B | 8.8B | 8.8B | 8.9B | 8.9B | 8.7B | 8.6B | 8.7B | 8.6B | 8.7B | 8.7B |
| 總負債 | 12.2B | 12.1B | 12.6B | 12.8B | 12.6B | 12.6B | 12.3B | 12.0B | 11.8B | 11.6B | 11.5B | – |
| 股東權益 | 1.0B | 903M | 906M | 733M | 542M | 472M | 493M | 144M | 48.0M | −589M | −555M | −737M |
| 負債比 | 92.4% | 93.1% | 93.3% | 94.6% | 95.9% | 96.4% | 96.1% | 98.8% | 99.6% | 105.3% | 105.1% | – |
| 淨現金(現金 − 有息負債) | −7.3B | −7.4B | −8.1B | −8.2B | −8.4B | −8.2B | −8.0B | −7.9B | −8.1B | −8.2B | −8.4B | −8.2B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 225M | – | – | 75.0M-1% | – | – | – | 76.0M | – | – | 114M |
| 資本支出 | – | 37.0M | – | – | 32.0M | – | – | – | 46.0M | – | – | 46.0M |
| 自由現金流 | – | 188M | – | – | 43.0M+43% | – | – | – | 30.0M | – | – | 68.0M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | 5.0M | – | – | 71.0M | – | – | – | 70.0M | – | – | 73.0M |
| 自由現金流率 | – | 12.9% | – | – | 2.8% | – | – | – | 1.8% | – | – | 4.4% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 10.8B
| 美國以外 | 4.6B | 42.6% | -4.5% |
|---|---|---|---|
| Europe And Canada | 1.6B | 14.9% | -8.2% |
| 美國 | 1.6B | 14.8% | +2.0% |
| Latin America Middle East Russia And Africa | 1.1B | 9.9% | +3.7% |
| Asia Pacific And Japan | 1.0B | 9.2% | -4.8% |
| 中國 | 829M | 7.7% | -2.1% |
| 其他國家 | 93.0M | 0.9% | -32.1% |
產品／服務2025 年度 · 1.00
| Nexplanon Implanon NXT 小計 | 921M | 92100000000.0% | -4.4% |
|---|---|---|---|
| Zetia 小計 | 342M | 34200000000.0% | +7.9% |
| Other Sundry Established Brands 小計 | 338M | 33800000000.0% | +3.0% |
| Atozet 小計 | 324M | 32400000000.0% | -31.5% |
| Other Non Opiod Pain Bone And Dermatology 小計 | 301M | 30100000000.0% | +2.0% |
| Arcoxia 小計 | 265M | 26500000000.0% | -1.9% |
| Follistim AQ 小計 | 264M | 26400000000.0% | +11.4% |
| Nasonex 小計 | 262M | 26200000000.0% | -5.1% |
| Singulair 小計 | 252M | 25200000000.0% | -29.8% |
| Renflexis 小計 | 251M | 25100000000.0% | -8.4% |
| Hadlima 小計 | 228M | 22800000000.0% | +60.6% |
| Cozaar Hyzaar 小計 | 219M | 21900000000.0% | -9.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 6.2B | -2.9% | 187M | 3.0% | 0.72 | 538M |
| FY2024 | 6.4B | +2.2% | 864M | 13.5% | 3.33 | 764M |
| FY2023 | 6.3B | +1.4% | 1.0B | 16.3% | 3.99 | 548M |
| FY2022 | 6.2B | -2.1% | 917M | 14.9% | 3.59 | 662M |
| FY2021 | 6.3B | -3.5% | 1.4B | 21.4% | 5.31 | 2.0B |
| FY2020 | 6.5B | -16.0% | 2.2B | 33.1% | 8.52 | 2.0B |
| FY2019 | 7.8B | – | 3.2B | 41.4% | 12.69 | 2.9B |